Boston Scientific Granted FDA Approval for Three Cardiac Products
Posted on: Tuesday, 26 February 2008, 12:01 CST
Boston Scientific has received FDA approval for three products in its Cardiac Rhythm Management business.
The company received approval for - the Confient implantable cardioverter defibrillator (ICD), which helps protect patients at risk of sudden cardiac death, the Livian cardiac resynchronization therapy defibrillator (CRT-D), which provides cardiac resynchronization and defibrillation therapies in one device, and for the upgraded Latitude Patient Management System, with enhanced remote monitoring capabilities.
Jim Tobin, president and CEO of Boston Scientific, said: "Our Cardiac Rhythm Management team is refocused on delivering therapy systems that meet physicians's needs for safety, reliability and better patient outcomes."
Source: Datamonitor
Related Articles
- Cardiac Disease Managers Improves Outcomes
- Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business
- MedSolutions Launches Outcomes-Focused Cardiac Imaging(TM): Industry's Most Rigorous Cardiac Imaging Management Product
- John Sculley Named to PDSHeart Board
- Philips' New 4D Ultrasound Transducer Provides Clinicians With Detailed Cardiovascular Images Needed for Heart Surgery on the Most Delicate Patients--Infants and Children
- Philips Introduces Advanced Hybrid-Imaging Technology and Expanded Information Management Capabilities to Enhance Diagnosis and Treatment for Cardiac Patients
- Backlash From Device Failures in Cardiac Rhythm Management Stunts Market Expansion in 2005
- Nurses' Symposium
- Cardiac Science Delivers Advanced Web-Enabled Cardiology Data Management System
- Future Directions*: American College of Chest Physicians Guidelines for the Prevention and Management of Postoperative Atrial Fibrillation After Cardiac Surgery
 |
 |
User Comments (0)
RSS Feeds